Business Context and Reporting Period
This Form 8-K Current Report, dated November 1, 2019, is filed by Veeva Systems Inc. (Veeva). The report announces the completion of the previously announced acquisition of Crossix Solutions Inc. (Crossix), a provider of clinical trial management solutions.
Key Financial Metrics and Transaction Details
The filing details the financial terms of the acquisition but does not report Veeva's consolidated revenue, profit, or cash flow for the period.
- Total Cash Consideration: Approximately $430 million paid to Crossix shareholders for outstanding shares and vested options, subject to customary purchase price adjustments.
- Employee Retention Equity: Anticipated grants to certain Crossix employees include approximately $80 million in restricted stock units (RSUs) and $40 million in stock options.
- Vesting Schedule: The RSUs and options granted to employees will vest over a period of 5.5 years.
- Debt and Liquidity: The filing text does not provide specific data on Veeva's current debt levels, liquidity position, or cash flow impact resulting from this transaction.
Material Changes Versus Prior Period
The primary material change is the consolidation of Crossix into Veeva's operations. All outstanding Crossix capital stock and vested options were cancelled upon closing. Unvested options were converted into Veeva Class A common stock options. No other material changes to Veeva's financial position or operations are disclosed in this specific filing.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the transaction closed pursuant to the Merger Agreement dated September 25, 2019. It notes that the Merger Agreement is incorporated by reference for contractual details.
Risks and Contingencies: The filing explicitly states that representations and warranties in the Merger Agreement were negotiated to allocate risk between parties and should not be relied upon as factual disclosures. It warns that these standards of materiality may differ from those under securities laws.
Future Filings: Financial statements of the acquired business and pro forma financial information are not included in this report. They are expected to be filed by amendment within 71 calendar days following the filing date.
Investor Verification Checklist
- Verify the final purchase price after customary adjustments to the $430 million base consideration.
- Review the upcoming amendment (within 71 days) for Crossix's standalone financial statements and pro forma impact on Veeva's earnings.
- Monitor future earnings releases for the integration progress and the impact of the $120 million in new employee equity grants on future compensation expenses.
- Confirm the specific terms of the converted unvested options and their exercise prices relative to Veeva's current stock price.